Balyasny Asset Management
ONCT

Balyasny Asset Management’s Oncternal Therapeutics, Inc. Common Stock ONCT Stock Holding History

Balyasny Asset Management’s Portfolio ONCT Stock Details ONCT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-608
Closed -$13K – 3378
2022
Q2 		$13K Buy
+608
New +$13.6K ﹤0.01% 2549

Other funds holding ONCT

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
QPW
Quantum Private Wealth Tampa, Florida $390M AUM 58.18% 1-Year Est. Return
BC
BIT Capital Berlin, Germany $2.07B AUM 157.17% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
BJL
Brighton Jones LLC Seattle, Washington $2.37B AUM 16.36% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return

Balyasny Asset Management's ONCT Position: Q3 2022 in Review

Balyasny Asset Management sold out of Oncternal Therapeutics, Inc. Common Stock (ONCT) in Q3 2022, closing a stake of 608 shares — an estimated $13K sold.

Balyasny Asset Management first reported a position in ONCT in Q2 2022 and held it in 1 quarter. The position peaked at $13K in Q2 2022. 61 funds tracked by Wall St. Rank hold ONCT as of Q3 2022.

  • Balyasny Asset Management reported no remaining Oncternal Therapeutics, Inc. Common Stock position as of Q3 2022 after selling out during the quarter.
  • Balyasny Asset Management sold 608 Oncternal Therapeutics, Inc. Common Stock shares in Q3 2022, an estimated $13K.
  • Balyasny Asset Management first reported a position in Oncternal Therapeutics, Inc. Common Stock in Q2 2022 and held it in 1 quarter.
  • Balyasny Asset Management's Oncternal Therapeutics, Inc. Common Stock position peaked at $13K in Q2 2022.
  • 61 funds tracked by Wall St. Rank held Oncternal Therapeutics, Inc. Common Stock as of Q3 2022.

Based on Balyasny Asset Management's 13F filing for Q3 2022, filed 15 Nov 2022.